Skip to main content

Advertisement

SpringerLink
Log in

Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?

  • Cardiovascular Physiology
  • Published:
Pflügers Archiv - European Journal of Physiology Aims and scope Submit manuscript

Abstract

Aldosterone and its receptor, the mineralocorticoid receptor (MR), play a key role in the regulation of reno-cardiovascular function as well as in the regulation of normal and abnormal reno-cardiovascular function, which are responsible for the variety of its functional responses. The underlying mechanisms are of genomic and nongenotropic nature. Prevention of critical arterial hypotension by NaCl retention and regulation of potassium homeostasis, which is of eminent importance for cardiovascular electrophysiology and rhythmogenesis, represent the good face of aldosterone in the cardiovascular system. Triggering of persistent arterial hypertension with all the detrimental secondary effects on heart, kidney, vessels, and brain represents the bad face of aldosterone/MR in the cardiovascular system. Blood pressure-independent reno-cardiovascular end organ damage represents the ugly face of MR activation and does not depend on elevated aldosterone concentrations. In this way, aldosterone/MR induces or facilitates inflammatory and fibrotic processes in a permissive milieu, created for example by angiotensin II or NaCl and characterized by enhanced oxidative stress, in vascular walls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Andersson B, Eriksson L, Fernandez O, Kolmodin CG, Oltner R (1972) Centrally mediated effects of sodium and angiotensin II on arterial blood pressure and fluid balance. Acta Physiol Scand 85:398–407

    Article  PubMed  CAS  Google Scholar 

  2. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268–275

    PubMed  CAS  Google Scholar 

  3. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8:35–40

    PubMed  CAS  Google Scholar 

  4. Bader M, Ganten D (2000) Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 78:130–139

    PubMed  CAS  Google Scholar 

  5. Bagrov AY, Fedorova OV, Dmitriev RI, French AW, Anderson DE (1996) Plasma marinobufagenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovasc Res 31:296–305

    PubMed  CAS  Google Scholar 

  6. Barbato JC, Rashid S, Mulrow PJ, Shapiro JI, Franco-Saenz R (2004) Mechanisms for aldosterone and spironolactone-induced positive inotropic actions in the rat heart. Hypertension 44:751–757

    PubMed  CAS  Google Scholar 

  7. Benitah JP, Perrier E, Gomez AM, Vassort G (2001) Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol (Lond) 537:151–160

    CAS  Google Scholar 

  8. Benitah JP, Vassort G (1999) Aldosterone upregulates Ca2+ current in adult rat cardiomyocytes. Circ Res 85:1139–1145

    PubMed  CAS  Google Scholar 

  9. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791–1800

    PubMed  CAS  Google Scholar 

  10. Blaustein MP, Zhang J, Chen L, Hamilton BP (2006) How does salt retention raise blood pressure? AJP - Regulatory, Integrative and Comparative Physiology 290:R514–R523

    PubMed  CAS  Google Scholar 

  11. Bokemeyer D, Schmitz U, Kramer HJ (2000) Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int 58:549–558

    PubMed  CAS  Google Scholar 

  12. Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893–901

    PubMed  CAS  Google Scholar 

  13. Brilla CG, Zhou G, Matsubara L, Weber KT (1994) Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26:809–820

    PubMed  CAS  Google Scholar 

  14. Bunda S, Liu P, Wang Y, Liu K, Hinek A (2007) Aldosterone induces elastin production in cardiac fibroblasts through activation of insulin-like growth factor-I receptors in a mineralocorticoid receptor-independent manner. Am J Pathol 171:809–819

    PubMed  CAS  Google Scholar 

  15. Callera GE, Montezano ACI, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM (2005) c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46:1032–1038

    PubMed  CAS  Google Scholar 

  16. Chun TY, Bloem LJ, Pratt JH (2003) Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology 144:1712–1717

    PubMed  CAS  Google Scholar 

  17. Delcayre C, Swynghedauw B (2002) Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 34:1577–1584

    PubMed  CAS  Google Scholar 

  18. Derfoul A, Robertson NM, Lingrel JB, Hall DJ, Litwack G (1998) Regulation of the human Na/K-ATPase beta 1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem 273:20702–20711

    PubMed  CAS  Google Scholar 

  19. Dorrance AM, Osborn HL, Grekin R, Webb RC (2001) Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281:R944–R950

    PubMed  CAS  Google Scholar 

  20. Duprez DA (2007) Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J Clin Hypertens (Greenwich) 9:13–18

    CAS  Google Scholar 

  21. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EGR, Smaili S, Periyasamy SM, Hariri IM, Fedorova L, Liu J, Wu L, Kahaleh MB, Xie Z, Malhotra D, Fedorova OV, Kashkin VA, Bagrov AY, Shapiro JI (2007) Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49:215–224

    PubMed  CAS  Google Scholar 

  22. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN (2005) aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111:3087–3094

    PubMed  CAS  Google Scholar 

  23. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC (2003) Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17:327–329

    PubMed  CAS  Google Scholar 

  24. Florian JA, Dorrance A, Webb RC, Watts SW (2001) Mineralocorticoids upregulate arterial contraction to epidermal growth factor. Am J Physiol Regul Integr Comp Physiol 281:R878–R886

    PubMed  CAS  Google Scholar 

  25. Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M, Myoishi M, Okuda H, Ogai A, Okada KI, Tsukamoto O, Koyama H, Hori M, Kitakaze M (2005) Aldosterone nongenomically worsens ischemia via protein kinase c-dependent pathways in hypoperfused canine hearts. Hypertension 46:113–117

    PubMed  CAS  Google Scholar 

  26. Funder JW (2005) The nongenomic actions of aldosterone. Endocr Rev 26:313–321

    PubMed  CAS  Google Scholar 

  27. Ganong WF, Mulrow PJ (1958) Rate of change in sodium and potassium excretion after injection of aldosterone into the aorta and renal artery of the dog. Am J Physiol 195:337–341

    PubMed  CAS  Google Scholar 

  28. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, d’Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110:1819–1825

    PubMed  CAS  Google Scholar 

  29. Geerling JC, Kawata M, Loewy AD (2006) Aldosterone-sensitive neurons in the rat central nervous system. J Comp Neurol 494:515–527

    PubMed  Google Scholar 

  30. Gekle M, Freudinger R, Mildenberger S, Schenk K, Marschitz I, Schramek H (2001) Rapid activation of Na+/H+-exchange in MDCK-cells by aldosterone involves MAP-kinases ERK1/2. Pflügers Arch 441:781–786

    PubMed  CAS  Google Scholar 

  31. Gekle M, Freudinger R, Mildenberger S, Silbernagl S (2002) Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol Renal Physiol 282:F669–F679

    PubMed  CAS  Google Scholar 

  32. Gekle M, Golenhofen N, Oberleithner H, Silbernagl S (1996) Rapid activation of Na+/H+-exchange by aldosterone in renal epithelial cells requires Ca2+ and stimulation of a plasma membrane proton conductance. Proc Natl Acad Sci USA 93:10500–10504

    PubMed  CAS  Google Scholar 

  33. Gekle M, Mildenberger S, Freudinger R, Grossmann C (2007) Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMC) induced by aldosterone. Pflugers Arch 454:403–413

    PubMed  CAS  Google Scholar 

  34. Gekle M, Silbernagl S, Wünsch S (1998) Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells. J Physiol 511:255–263

    PubMed  CAS  Google Scholar 

  35. Goodfriend TL (2006) Aldosterone—a hormone of cardiovascular adaptation and maladaptation. J Clin Hypertens 8:133–139

    CAS  Google Scholar 

  36. Grossmann C, Freudinger R, Mildenberger S, Krug AW, Gekle M (2004) Evidence for epidermal growth factor receptor as negative-feedback control in aldosterone-induced Na+ reabsorption. Am J Physiol Renal Physiol 286:F1226–F1231

    PubMed  CAS  Google Scholar 

  37. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19:1697–1710

    PubMed  CAS  Google Scholar 

  38. Grossmann C, Freudinger R, Mildenberger S, Husse B, Gekle M (2008) EF domains are sufficient for nongenomic mineralocorticoid receptor actions. J Biol Chem 283:7109–7116

    PubMed  CAS  Google Scholar 

  39. Grossmann C, Gekle M (2007) Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors? Mol Cell Endocrinol 277:6–12

    PubMed  CAS  Google Scholar 

  40. Grossmann C, Krug AW, Freudinger R, Mildenberger S, Volker K, Gekle M (2007) Aldosterone-induced epidermal growth factor receptor (EGFR) expression: interaction between the human mineralocorticoid receptor and the human egfr promoter. Am J Physiol Endocrinol Metab 292:1790–1800

    Google Scholar 

  41. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y (2007) Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expressions in aldosterone-induced hypertension: the possible role of local rennin–angiotensin system. Endocrinology 148:1688–1696

    PubMed  CAS  Google Scholar 

  42. Huang BS, White RA, Ahmad M, Jeng AY, Leenen FHH (2008) Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in wistar rats. AJP—Regulatory, Integrative and Comparative Physiology 295:R166–R172

    PubMed  CAS  Google Scholar 

  43. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004) Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the rennin–angiotensin system. Am J Hypertens 17:597–603

    PubMed  CAS  Google Scholar 

  44. Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643–650

    PubMed  CAS  Google Scholar 

  45. Jernigan NL, Drummond HA (2005) Vascular ENaC proteins are required for renal myogenic constriction. AJP - Renal Physiology 289:F891–F901

    PubMed  CAS  Google Scholar 

  46. Jiang W, Yang JH, Wang Sh, Pan CS, Qi YF, Zhao J, Tang CS (2004) Effects of adrenomedullin on aldosterone-induced cell proliferation in rat cardiac fibroblasts. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1690:265–275

    CAS  Google Scholar 

  47. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20:1546–1548

    PubMed  CAS  Google Scholar 

  48. Kagiyama S, Qian K, Kagiyama T, Phillips MI (2003) Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy. Hypertension 41:824–829

    PubMed  CAS  Google Scholar 

  49. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI (2002) Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106:909–912

    PubMed  CAS  Google Scholar 

  50. Kennedy DJ, Vetteth S, Periyasamy SM, Kanj M, Fedorova L, Khouri S, Kahaleh MB, Xie Z, Malhotra D, Kolodkin NI, Lakatta EG, Fedorova OV, Bagrov AY, Shapiro JI (2006) Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47:488–495

    PubMed  CAS  Google Scholar 

  51. Klein K, Henk W (1963) [Clinical experimental studies on the influence of aldosterone on hemodynamics and blod coagulation.]. Z Kreislaufforsch 52:40–53

    PubMed  CAS  Google Scholar 

  52. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, Matsuoka H (2006) Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47:671–679

    PubMed  CAS  Google Scholar 

  53. Kolla V, Robertson NM, Litwack G (1999) Identification of a mineralocorticoid/glucocorticoid response element in the human Na/K ATPase [alpha]1 gene promoter. Biochem Biophys Res Commun 266:5–14

    PubMed  CAS  Google Scholar 

  54. Krug AW, Grossmann C, Schuster C, Freudinger R, Mildenberger S, Govindan MV, Gekle M (2003) Aldosterone stimulates epidermal growth factor receptor (EGFR) expression. J Biol Chem 278:43060–43066

    PubMed  CAS  Google Scholar 

  55. Krug AW, Schuster C, Gassner B, Freudinger R, Mildenberger S, Troppmair J, Gekle M (2002) Human EGF receptor 1 (HER1) expression renders CHO cells sensitive to alternative aldosterone signaling. J Biol Chem 277:45892–45897

    PubMed  CAS  Google Scholar 

  56. Kusche-Vihrog K, Sobczak K, Bangel N, Wilhelmi M, Nechyporuk-Zloy V, Schwab A, Schillers H, Oberleithner H (2007) Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflugers Arch 455:849–857

    PubMed  Google Scholar 

  57. Kuster GM, Kotlyar E, Rude MK, Siwik DA, Liao R, Colucci WS, Sam F (2005) Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 111:420–427

    PubMed  CAS  Google Scholar 

  58. Lal A, Veinot JP, Leenen FHH (2004) Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res 64:437–447

    PubMed  CAS  Google Scholar 

  59. Lalevee N, Rebsamen MC, Barrere-Lemaire S, Perrier E, Nargeot J, Benitah JP, Rossier MF (2005) Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 67:216–224

    PubMed  CAS  Google Scholar 

  60. Lam EYM, Funder JW, Nikolic-Paterson DJ, Fuller PJ, Young MJ (2006) Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in DOC/salt rats. Endocrinology 147:3623–3629

    PubMed  CAS  Google Scholar 

  61. Le Moellic C, Ouvrard-Pascaud A, Capurro C, Cluzeaud F, Fay M, Jaisser F, Farman N, Blot-Chabaud M (2004) Early nongenomic events in aldosterone action in renal collecting duct cells: PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J Am Soc Nephrol 15:1145–1160

    PubMed  Google Scholar 

  62. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD (2003) Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108:2400–2406

    PubMed  CAS  Google Scholar 

  63. Losel R, Wehling M (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4:46–56

    PubMed  Google Scholar 

  64. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69:1064–1072

    PubMed  CAS  Google Scholar 

  65. Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, Bianchi G (2001) Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38:198–203

    PubMed  CAS  Google Scholar 

  66. Mathew JT, Patni H, Chaudhary AN, Liang W, Gupta A, Chander PN, Ding G, Singhal PC (2008) Aldosterone induces mesangial cell apoptosis both in vivo and in vitro. AJP - Renal Physiology 295:73–81

    Google Scholar 

  67. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC (2004) Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 109:2792–2800

    PubMed  CAS  Google Scholar 

  68. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428–435

    PubMed  CAS  Google Scholar 

  69. Mejia-Villet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA (2007) Renal ischemia/reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. AJP - Renal Physiology 293:78–86

    Google Scholar 

  70. Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA (2005) Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev 85:679–715

    PubMed  CAS  Google Scholar 

  71. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET (2005) Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146:973–980

    PubMed  CAS  Google Scholar 

  72. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M (2005) Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97:434–442

    PubMed  CAS  Google Scholar 

  73. Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M, Gollasch M, Wresche S, Luft FC, Muller DN, Fiebeler A (2008) Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension 51:1372–1378

    PubMed  CAS  Google Scholar 

  74. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz RM (2008) Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive rhoA pathways. Arterioscler Thromb Vasc Biol 28:1511–1518

    PubMed  CAS  Google Scholar 

  75. Moura AM, Worcel M (1984) Direct action of aldosterone on transmembrane 22Na efflux from arterial smooth muscle. Rapid and delayed effects. Hypertension 6:425–430

    PubMed  CAS  Google Scholar 

  76. Mullins LJ, Bailey MA, Mullins JJ (2006) Hypertension, kidney, and transgenics: a fresh perspective. Physiol Rev 86:709–746

    PubMed  CAS  Google Scholar 

  77. Muto T, Ueda N, Opthof T, Ohkusa T, Nagata K, Suzuki S, Tsuji Y, Horiba M, Lee JK, Honjo H, Kamiya K, Kodama I, Yasui K (2007) Aldosterone modulates If current through gene expression in cultured neonatal rat ventricular myocytes. AJP—Heart and Circulatory Physiology 293:2710–2718

    Google Scholar 

  78. Nagai Y, Miyata K, Sun GP, Rahman M, Kimura S, Miyatake A, Kiyomoto H, Kohno M, Abe Y, Yoshizumi M, Nishiyama A (2005) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46:1039–1045

    PubMed  CAS  Google Scholar 

  79. Nagase M, Matsui H, Shibata S, Gotoda T, Fujita T (2007) Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor. Role of oxidative stress. Hypertension 50:877–883

    PubMed  CAS  Google Scholar 

  80. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T (2006) Podocyte injury underlies the glomerulopathy of dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47:1084–1093

    PubMed  CAS  Google Scholar 

  81. Nagata K, Obata K, Xu J, Ichihara S, Noda A, Kimata H, Kato T, Izawa H, Murohara T, Yokota M (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47:656–664

    PubMed  CAS  Google Scholar 

  82. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H (2005) Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 28:925–936

    PubMed  CAS  Google Scholar 

  83. Neumann S, Huse K, Semrau R, Diegeler A, Gebhardt R, Buniatian GH, Scholz GH (2002) Aldosterone and D-Glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 39:756–760

    PubMed  CAS  Google Scholar 

  84. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, Yoshida T, Hiroe M, Imanaka-Yoshida K (2007) Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49:261–268

    PubMed  CAS  Google Scholar 

  85. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43:841–848

    PubMed  CAS  Google Scholar 

  86. Northcott C, Florian JA, Dorrance A, Watts SW (2001) Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 38:1337–1341

    PubMed  CAS  Google Scholar 

  87. Oberleithner H, Riethmuller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M (2007) Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Nat Acad Sci 104:16281–16286

    PubMed  CAS  Google Scholar 

  88. Obradovic D, Tirard M, Nemethy Z, Hirsch O, Gronemeyer H, Almeida OFX (2004) DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells—toward a basis for the opposite actions elicited by two nuclear receptors? Mol Pharmacol 65:761–769

    PubMed  CAS  Google Scholar 

  89. Ortlund EA, Bridgham JT, Redinbo MR, Thornton JW (2007) Crystal structure of an ancient protein: evolution by conformational epistasis. Science 317:1544–1548

    PubMed  CAS  Google Scholar 

  90. Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, Perrier R, Soukaseum C, Cat AND, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B, Jaisser F (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111:3025–3033

    PubMed  CAS  Google Scholar 

  91. Park JB, Schiffrin EL (2001) ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37:1444–1449

    PubMed  CAS  Google Scholar 

  92. Pascual-Le Tallec L, Kirsh O, Lecomte MC, Viengchareun S, Zennaro MC, Dejean A, Lombes M (2003) Protein inhibitor of activated signal transducer and activator of transcription 1 interacts with the N-terminal domain of mineralocorticoid receptor and represses its transcriptional activity: implication of small ubiquitin-related modifier 1 modification. Mol Endocrinol 17:2529–2542

    CAS  Google Scholar 

  93. Pascual-Le Tallec L, Lombes M (2005) The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 19:2211–2221

    PubMed  CAS  Google Scholar 

  94. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM, Benitah JP (2004) Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110:776–783

    PubMed  CAS  Google Scholar 

  95. Perrier R, Richard S, Sainte-Marie Y, Rossier BC, Jaisser F, Hummler E, Benitah JP (2005) A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J Physiol (Lond) 569:153–162

    CAS  Google Scholar 

  96. Pfau A, Grossmann C, Freudinger R, Mildenberger S, Benesic A, Gekle M (2007) Ca2+ but not H2O2 modulates GRE-element activation by the human mineralocorticoid receptor in HEK cells. Mol Cell Endocrinol 264:35–43

    PubMed  CAS  Google Scholar 

  97. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321

    PubMed  CAS  Google Scholar 

  98. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717

    PubMed  CAS  Google Scholar 

  99. Pitt B (2004) Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217:53–58

    PubMed  CAS  Google Scholar 

  100. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL (2003) Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42:49–55

    PubMed  CAS  Google Scholar 

  101. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EAG, Goellner JJ, Funder JW, McMahon EG (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93:69–76

    PubMed  CAS  Google Scholar 

  102. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M, Stewart PM (2005) Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 112:1435–1443

    PubMed  CAS  Google Scholar 

  103. Rad AK, Balment RJ, Ashton N (2005) Rapid natriuretic action of aldosterone in the rat. J Appl Physiol 98:423–428

    PubMed  CAS  Google Scholar 

  104. Rahman M, Nishiyama A, Guo P, Nagai Y, Zhang GX, Fujisawa Y, Fan YY, Kimura S, Hosomi N, Omori K, Abe Y, Kohno M (2006) Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. J Pharmacol Exp Ther 318:1323–1329

    PubMed  CAS  Google Scholar 

  105. Rebsamen MC, Perrier E, Gerber-Wicht C, Benitah JP, Lang U (2004) Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. Endocrinology 145:3135–3142

    PubMed  CAS  Google Scholar 

  106. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. (1998) Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31:451–458

    PubMed  CAS  Google Scholar 

  107. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E (2002) Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143:4828–4836

    PubMed  CAS  Google Scholar 

  108. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, McMahon EG, Delyani JA (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. AJP - Heart and Circulatory Physiology 283:H1802–H1810

    PubMed  CAS  Google Scholar 

  109. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V (2003) Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166:345–349

    PubMed  CAS  Google Scholar 

  110. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A (2001) Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 134:224–232

    PubMed  CAS  Google Scholar 

  111. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F, PAPY Study Participants (2006) Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 48:232–238

    PubMed  CAS  Google Scholar 

  112. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A (2008) Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension 52:721–728

    PubMed  CAS  Google Scholar 

  113. Rougier JS, Muller O, Berger S, Centeno G, Schutz G, Firsov D, Abriel H (2007) Mineralocorticoid receptor is essential for corticosteroid-induced up-regulation of L-type calcium currents in cultured neonatal cardiomyocytes. Pflugers Arch 456:407–412

    PubMed  Google Scholar 

  114. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F (2005) Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46:555–561

    PubMed  CAS  Google Scholar 

  115. Sainte-Marie Y, Cat AND, Perrier R, Mangin L, Soukaseum C, Peuchmaur M, Tronche F, Farman N, Escoubet B, Benitah JP, Jaisser F (2007) Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB J 21:3133–3141

    PubMed  CAS  Google Scholar 

  116. Schmidt BM, Horisberger K, Feuring M, Schultz A, Wehling M (2005) Aldosterone blunts human baroreflex sensitivity by a nongenomic mechanism. Exp Clin Endocrinol Diabetes 113:252–256

    PubMed  CAS  Google Scholar 

  117. Schmidt BMW, Georgens AC, Martin N, Tillmann H-C, Feuring M, Christ M, Wehling M (2001) Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab 86:761–767

    PubMed  CAS  Google Scholar 

  118. Schmidt BMW, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE (2003) Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42:156–160

    PubMed  CAS  Google Scholar 

  119. Schmidt BMW, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE (2006) Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47:650–655

    PubMed  CAS  Google Scholar 

  120. Schneider SW, Yano Y, Sumpio BE, Jena BP, Geibel JP, Gekle M, Oberleithner H (1997) Rapid aldosterone-induced cell volume increase of endothelial cells measured by the atomic force microscope. Cell Biol Int 21:759–768

    PubMed  CAS  Google Scholar 

  121. Schoner W, Scheiner-Bobis G (2007) Endogenous and exogenous cardiac glycosides: Their roles in hypertension, salt metabolism, and cell growth. AJP - Cell Physiology 293:509–536

    Google Scholar 

  122. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T (2007) Podocyte as the target for aldosterone: roles of oxidative stress and sgk1. Hypertension 49:355–364

    PubMed  CAS  Google Scholar 

  123. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C (1999) Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99:2694–2701

    PubMed  CAS  Google Scholar 

  124. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C (1998) Myocardial production of aldosterone and corticosterone in the rat. physiological regulation. J Biol Chem 273:4883–4891

    PubMed  CAS  Google Scholar 

  125. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T (1953) Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia 9:333–335

    PubMed  CAS  Google Scholar 

  126. Skott O, Uhrenholt TR, Schjerning J, Hansen PBL, Rasmussen LE, Jensen BL (2006) Rapid actions of aldosterone in vascular health and disease–friend or foe? Pharm Ther 111:495–507

    CAS  Google Scholar 

  127. Smith CL, He Q, Huang L, Foster E, Puschett JB (2007) Marinobufagenin interferes with the function of the mineralocorticoid receptor. Biochem Biophys Res Commun 356:930–934

    PubMed  CAS  Google Scholar 

  128. Smith JB, Wade MB, Fineberg NS, Weinberger MH (1988) Sodium transport parameters in erythrocytes of patients with primary aldosteronism. Hypertension 11:141–146

    PubMed  CAS  Google Scholar 

  129. Spach C, Streeten DH (1964) Retardation of sodium exchange in dog erythrocytes by physiological concentrations of aldosterone, in vitro. J Clin Invest 43:217–227

    PubMed  CAS  Google Scholar 

  130. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR (2007) Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 148:3773–3780

    PubMed  CAS  Google Scholar 

  131. Stockand JD, Meszaros JG (2003) Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 284:H176–H184

    PubMed  CAS  Google Scholar 

  132. Sugiyama T, Yoshimoto T, Tsuchiya K, Gochou N, Hirono Y, Tateno T, Fukai N, Shichiri M, Hirata Y (2005) Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 146:3900–3906

    PubMed  CAS  Google Scholar 

  133. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT (2002) Aldosterone-induced inflammation in the rat heart—role of oxidative stress. Am J Pathol 161:1773–1781

    PubMed  CAS  Google Scholar 

  134. Tepel M, Husseini S, Zidek W (1993) Effect of spironolactone on cytosolic free sodium concentration in platelets from hypertensive patients with primary aldosteronism. Eur J Clin Pharmacol 44(Suppl 1):S51–S52

    PubMed  Google Scholar 

  135. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G (2000) Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. J Clin Invest 106:225–234

    PubMed  CAS  Google Scholar 

  136. Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD (2002) Adenoviral-directed expression of the Type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135–142

    PubMed  CAS  Google Scholar 

  137. Tsugita M, Iwasaki Y, Nishiyama M, Taguchi T, Shinahara M, Taniguchi Y, Kambayashi M, Terada Y, Hashimoto K (2008) Differential regulation of 11[beta] -hydroxysteroid dehydrogenase type-1 and -2 gene transcription by proinflammatory cytokines in vascular smooth muscle cells. Life Sciences 83:426–432

    PubMed  CAS  Google Scholar 

  138. Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S, DeFreitas G, Entman M, Carabello BA, Roberts R, Marian AJ (2004) Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 109:1284–1291

    PubMed  CAS  Google Scholar 

  139. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, Sorensen GL, Skott O (2003) Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93:1258–1266

    PubMed  CAS  Google Scholar 

  140. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002) Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40:504–510

    PubMed  CAS  Google Scholar 

  141. Wagner M, Rudakova E, Volk T (2008) Aldosterone-induced changes in the cardiac L-type Ca2+ current can be prevented by antioxidants in vitro and are absent in rats on low salt diet. Pflugers Arch doi:10.1007/s00424-008-0518-1

  142. Wang H, Shimosawa T, Matsui H, Kaneko T, Ogura S, Uetake Y, Takenaka K, Yatomi Y, Fujita T (2008) Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens 26:1453–1462

    PubMed  CAS  Google Scholar 

  143. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K (1993) Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol 88(Suppl 1):107–124

    PubMed  CAS  Google Scholar 

  144. Wehling M, Spes CH, Win N, Janson CP, Schmidt BMW, Theisen K, Christ M (1998) Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 83:3517–3522

    PubMed  CAS  Google Scholar 

  145. Williams JS, Williams GH (2003) 50th anniversary of aldosterone. J Clin Endocrinol Metab 88:2364–2372

    PubMed  CAS  Google Scholar 

  146. Williams SS (2007) Advances in genetic hypertension. Curr Opin Pediatr 19:192–198

    PubMed  Google Scholar 

  147. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Shono M, Suzuki S, Sakamoto T, Saito Y, Nakao K, Yasue H, Ogawa H (2005) Direct effects of aldosterone on cardiomyocytes in the presence of normal and elevated extracellular sodium. Endocrinology 147:1314–1321

    PubMed  Google Scholar 

  148. Young M, Funder JW (2004) Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/ salt-treated rats. Endocrinology 145:3153–3157

    PubMed  CAS  Google Scholar 

  149. Yu Y, Wei SG, Zhang ZH, Gomez-Sanchez E, Weiss RM, Felder RB (2008) Does aldosterone upregulate the brain rennin–angiotensin system in rats with heart failure? Hypertension 51:727–733

    PubMed  CAS  Google Scholar 

  150. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (rales). Circulation 102:2700–2706

    PubMed  CAS  Google Scholar 

  151. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J (2006) An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res 99:528–536

    PubMed  CAS  Google Scholar 

  152. Zhang ZH, Kang YM, Yu Y, Wei SG, Schmidt TJ, Johnson AK, Felder RB (2006) 11 beta-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension 48:127–133

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Work was performed in the authors’ laboratory and was supported by the Deutsche Forschungsgemeinschaft (DFG).

Author information

Authors and Affiliations

  1. Julius-Bernstein-Institut für Physiologie, Universität Halle-Wittenberg, Magdeburger Strasse 6, 06097, Halle (Saale), Germany

    Michael Gekle & Claudia Grossmann

Authors
  1. Michael Gekle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Grossmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Gekle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gekle, M., Grossmann, C. Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflugers Arch - Eur J Physiol 458, 231–246 (2009). https://doi.org/10.1007/s00424-008-0616-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00424-008-0616-0

Keywords

Search

Navigation